Clinical characteristics of the study population according to diagnosis and compared with the patients who were not included due to missing date for symptom onset and/or diagnosis
| RA | PSA | AS | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Study population | Not included | p Value | Study population | Not included | p Value | Study population | Not included | p Value | |
| N | 10 416 | 3769 | – | 1970 | 920 | – | 1335 | 717 | – |
| Women (%) | 73.2 | 72.5 | 0.41 | 56.0 | 56.6 | 0.75 | 29.1 | 27.8 | 0.51 |
| Age at DANBIO entry (years) (mean (SD)) | 58.9 (14.0) | 58.8 (14.3) | 0.81 | 48.8 (13.0) | 50.3 (12.5) | <0.01 | 40.8 (12.4) | 43.2 (12.6) | <0.01 |
| Patient global VAS score at entry (VAS, 0–100 mm) (mean (SD)) | 46.4 (28.5) n=9045 | 53.7 (27.0) n=3015 | <0.01 | 51.4 (28.7) n=1736 | 57.3 (27.5) n=811 | <0.01 | 55.8 (26.2) n=996 | 57.1 (26.9) n=598 | 0.34 |
| DAS28-CRP at entry (mean (SD)) | 3.9 (1.5) n=8180 | 4.4 (1.6) n=2795 | <0.01 | 3.7 (1.4) n=1432 | 4.1 (1.5) n=657 | <0.01 | 3.0 (1.1) n=295 | 3.5 (1.3) n=195 | <0.01 |
| HAQ at entry (mean (SD)) | 0.9 (0.7) n=9028 | 1.1 (0.8) n=2935 | <0.01 | 0.8 (0.6) n=1619 | 0.9 (0.7) n=752 | <0.01 | 0.7 (0.6) n=173 | 0.9 (0.9) n=167 | <0.01 |
| Ever biological treatment (% of patients) | 31.1 | 57.2 | <0.01 | 44.7 | 53.2 | <0.01 | 69.7 | 77.8 | <0.01 |
AS, ankylosing spondylitis; DAS28-CRP, disease activity score based on C-reactive protein and four variables; HAQ, Health Assessment Questionnaire; PSA, psoriatic arthritis; RA, rheumatoid arthritis; VAS: visual analogue scale.